|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Latini DM, Lerner SP, Wade SW, Lee DW and
Quale DZ: Bladder cancer detection, treatment and outcomes:
Opportunities and challenges. Urology. 75:334–339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lokeshwar VB, Habuchi T, Grossman HB,
Murphy WM, Hautmann SH, Hemstreet GP III, Bono AV, Getzenberg RH,
Goebell P, Schmitz-Dräger BJ, et al: Bladder tumor markers beyond
cytology: International consensus panel on bladder tumor markers.
Urology. 66:35–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaymaz E, Ozer E, Unverdi H and
Hucumenoglu S: Evaluation of MUC1 and P53 expressions in
noninvasive papillary urothelial neoplasms of bladder, their
relationship with tumor grade and role in the differential
diagnosis. Indian J Pathol Microbiol. 60:510–514. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Z, Wang X, Zhang D, Yu Y, Cai L and
Zhang C: Long non-coding RNA urothelial carcinoma-associated 1 as a
tumor biomarker for the diagnosis of urinary bladder cancer. Tumour
Biol. 39:10104283177099902017.PubMed/NCBI
|
|
7
|
Peng F, Li H, Xiao H, Li L, Li Y and Wu Y:
Identification of a three miRNA signature as a novel potential
prognostic biomarker in patients with bladder cancer. Oncotarget.
8:105553–105560. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duan R, Zhang Z, Zheng F, Wang L, Guo J,
Zhang T, Dai X, Zhang S, Yang D, Kuang R, et al: Combining protein
and mirna quantification for bladder cancer analysis. ACS Appl
Mater Interfaces. 9:23420–23427. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng C, Sun P, Hu J, Feng H, Li M, Liu G,
Pan Y and Feng Y, Xu Y, Feng K and Feng Y: miRNA-556-3p promotes
human bladder cancer proliferation, migration and invasion by
negatively regulating DAB2IP expression. Int J Oncol. 50:2101–2112.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirata H, Ueno K, Shahryari V, Tanaka Y,
Tabatabai ZL, Hinoda Y and Dahiya R: Oncogenic miRNA-182-5p targets
Smad4 and RECK in human bladder cancer. PLoS One. 7:e510562012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao X, He W, Li J, Huang S, Wan X, Luo H
and Wu D: MiRNA-125b inhibits proliferation and migration by
targeting SphK1 in bladder cancer. Am J Transl Res. 7:2346–2354.
2015.PubMed/NCBI
|
|
12
|
Zeng T, Peng L, Chao C, Fu B, Wang G, Wang
Y and Zhu X: miR-451 inhibits invasion and proliferation of bladder
cancer by regulating EMT. Int J Clin Exp Pathol. 7:7653–7662.
2014.PubMed/NCBI
|
|
13
|
Du M, Shi D, Yuan L, Li P, Chu H, Qin C,
Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in
plasma are potential novel biomarkers for bladder cancer. Sci Rep.
5:104372015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alva A, Friedlander T, Clark M, Huebner T,
Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, et
al: Circulating tumor cells as potential biomarkers in bladder
cancer. J Urol. 194:790–798. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scheffer AR, Holdenrieder S, Kristiansen
G, von Ruecker A, Müller SC and Ellinger J: Circulating microRNAs
in serum: Sovel biomarkers for patients with bladder cancer? World
J Urol. 32:353–358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin Q, Li XJ and Cao PG: miR-26b enhances
radiosensitivity of hepatocellular carcinoma cells by targeting
EphA2. Iran J Basic Med Sci. 19:851–857. 2016.PubMed/NCBI
|
|
17
|
Gasque Schoof CR, Izzotti A, Jasiulionis
MG and Vasques Ldos R: The roles of miR-26, miR-29 and miR-203 in
the silencing of the epigenetic machinery during melanocyte
transformation. Biomed Res Int. 2015:6347492015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang F, Wang H, Jiang Z, Hu A, Chu L, Sun
Y and Han J: MicroRNA19a mediates gastric carcinoma cell
proliferation through the activation of nuclear factor-κB. Mol Med
Rep. 12:5780–5786. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wadhwa N, Jatawa SK and Tiwari A:
Republished: Non-invasive urine based tests for the detection of
bladder cancer. Postgrad Med J. 89:352–357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wadhwa N, Jatawa SK and Tiwari A:
Non-invasive urine based tests for the detection of bladder cancer.
J Clin Pathol. 65:970–975. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rossi R, Lichtner M, Iori F, Ermocida A,
Mascia C, Mengoni F, Sauzullo I, Dini D, Mastroianni CM and Vullo
V: Dendritic cells in blood and urine samples from bladder cancer
patients undergoing BCG immunotherapy. Arch Ital Urol Androl.
85:157–163. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blanca A, Cheng L, Montironi R, Moch H,
Massari F, Fiorentino M, Raspollini MR, Scarpelli M and
Lopez-Beltran A: Mirna expression in bladder cancer and their
potential role in clinical practice. Curr Drug Metab. 18:712–722.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blick C, Ramachandran A, McCormick R,
Wigfield S, Cranston D, Catto J and Harris AL: Identification of a
hypoxia-regulated miRNA signature in bladder cancer and a role for
miR-145 in hypoxia-dependent apoptosis. Br J Cancer. 113:634–644.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Braicu C, Cojocneanu-Petric R, Chira S,
Truta A, Floares A, Petrut B, Achimas-Cadariu P and Berindan-Neagoe
I: Clinical and pathological implications of miRNA in bladder
cancer. Int J Nanomedicine. 10:791–800. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui X, Kong C, Zhu Y, Zeng Y, Zhang Z, Liu
X, Zhan B, Piao C and Jiang Z: miR-130b, an onco-miRNA in bladder
cancer, is directly regulated by NF-κB and sustains NF-κB
activation by decreasing Cylindromatosis expression. Oncotarget.
7:48547–48561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Egawa H, Jingushi K, Hirono T, Ueda Y,
Kitae K, Nakata W, Fujita K, Uemura M, Nonomura N and Tsujikawa K:
The miR-130 family promotes cell migration and invasion in bladder
cancer through FAK and Akt phosphorylation by regulating PTEN. Sci
Rep. 6:205742016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X, Cheng Y, Li P, Tao J, Deng X,
Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21
diminishes aerobic glycolysis in bladder cancer T24 cells via the
PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mundhenk J, Hennenlotter J, Zug L,
Alloussi SH, Todenhoefer T, Gakis G, Aufderklamm S, Scharpf M,
Kuehs U, Stenzl A and Schwentner C: Evidence for PTEN-independent
Akt activation and Akt-independent p27 (Kip1) expression in
advanced bladder cancer. Oncol Lett. 2:1089–1093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang N, Lee HW, Lim JE, Jeong DE, Song
HJ, Kim S, Nam DH, Sung HH, Jeong BC, Seo SI, et al: Establishment
and antitumor effects of dasatinib and PKI-587 in BD-138T, a
patient-derived muscle invasive bladder cancer preclinical platform
with concomitant EGFR amplification and PTEN deletion. Oncotarget.
7:51626–51639. 2016. View Article : Google Scholar : PubMed/NCBI
|
